REFERENCES
1. Diederichs C, Neuhauser H. Regional variations in hypertension prevalence and management in Germany: results from the German Health Interview and Examination Survey (DEGS1). J Hypertens 2014;32:1405-13.
2. de Burgos-Lunar C, Jiménez-García R, Salinero-Fort MA, Gómez-Campelo P, Gil A, Abánades-Herranz JC, Cárdenas-Valladolid J, del Cura-González I. Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009. PLoS One 2014;9:e86713.
3. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009;27:963-75 .
4. Basu S, Millett C. Social epidemiology of hypertension in middle-income countries: determinants of prevalence, diagnosis, treatment, and control in the WHO SAGE study. Hypertension 2013;62:18-26.
5. Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, Facchetti R, Redon J, Mancia G, Grassi G. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens 2013;31:2018-24.
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
7. Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep 2015;17:85.
8. Bernatova I. Endothelial dysfunction in experimental models of arterial hypertension: cause or consequence? Biomed Res Int 2014;2014:598271.
10. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int 2014;2014:406960.
11. de Faria AP, Fontana V, Modolo R, Barbaro NR, Sabbatini AR, Pansani IF, Ferreira-Melo SE, Moreno H. Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. Clin Chim Acta 2014;433:179-83.
12. Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, Lee J, Lee MY, Lee SM, Kang DH, Lee BH. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J 2014;28:3197-204.
13. Wong WT, Tian XY, Huang Y. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS, BMP4, and ROS-dependent COX-2-derived prostanoids. J Cardiovasc Pharmacol 2013;61:204-14.
14. Martynowicz H, Janus A, Nowacki D, Mazur G. The role of chemokines in hypertension. Adv Clin Exp Med 2014;23:319-25.
15. Berezin AE. Preconditioned endothelial progenitor cells as biomarker of vascular reparation? Insights in Biomed 2017;2:4-7.
16. Shan Y, Lin J, Xu P, Zeng M, Lin H, Yan H. The combined effect of hypertension and type 2 diabetes mellitus on aortic stiffness and endothelial dysfunction: an integrated study with high-resolution MRI. Magn Reson Imaging 2014;32:211-6.
17. Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflamm Res 2018;67:391-405.
18. Triches CB, Mayer S, Quinto BMR, Batista MC, Zanella MT. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension. J Clin Hypertens (Greenwich) 2018; doi: 10.1111/jch.13269.
19. Berezin AE. Endothelial progenitor cells dysfunction and impaired tissue reparation: the missed link in diabetes mellitus development. Diabetes Metab Syndr 2017;11:215-20.
20. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-6.
21. Asahara T. Endothelial progenitor cells for vascular medicine. Yakugaku Zasshi 2007;127:841-5. (in Japanese)
22. Patel J, Donovan P, Khosrotehrani K. Concise review: functional definition of endothelial progenitor cells: a molecular perspective. Stem Cells Transl Med 2016;5:1302-6.
23. Yi C, Xia W, Zheng Y, Zhang L, Shu M, Liang J, Han Y, Guo S. Transplantation of endothelial progenitor cells transferred by vascular endothelial growth factor gene for vascular regeneration of ischemic flaps. J Surg Res 2006;135:100-6.
24. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8.
25. Murohara T. Angiogenesis and vasculogenesis for therapeutic neovascularization. Nagoya J Med Sci 2003;66:1-7.
26. Charlene A. McQueen, editor-in-chief. Comprehensive toxicology. Amsterdam: Elsevier Science; 2018. pp. 130-82.
27. Böldicke T, Tesar M, Griesel C, Rohde M, Gröne HJ, Waltenberger J, Kollet O, Lapidot T, Yayon A, Weich H. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem Cells 2001;19:24-36.
28. Ferreras C, Cole CL, Urban K, Jayson GC, Avizienyte E. Segregation of late outgrowth endothelial cells into functional endothelial CD34- and progenitor-like CD34+ cell populations. Angiogenesis 2015;18:47-68.
29. Popa ER, Harmsen MC, Tio RA, van der Strate BW, Brouwer LA, Schipper M, Koerts J, De Jongste MJ, Hazenberg A, Hendriks M, van Luyn MJ. Circulating CD34+ progenitor cells modulate host angiogenesis and inflammation in vivo. J Mol Cell Cardiol 2006;41:86-96.
31. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;23:1185-9.
32. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002;105:732-8.
33. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107:1322-8.
34. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A, Egashira K. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004;109:2454-61.
35. Pasut A, Chang NC, Gurriaran-Rodriguez U, Faulkes S, Yin H, Lacaria M, Ming H, Rudnicki MA. Notch signaling rescues loss of satellite cells lacking Pax7 and promotes brown adipogenic differentiation. Cell Rep 2016;16:333-43.
36. Kachamakova-Trojanowska N, Bukowska-Strakova K, Zukowska M, Dulak J, Jozkowicz A. The real face of endothelial progenitor cells - circulating angiogenic cells as endothelial prognostic marker? Pharmacol Rep 2015;67:793-802.
37. Fang S, Wei J, Pentinmikko N, Leinonen H, Salven P. Generation of functional blood vessels from a single c-kit+ adult vascular endothelial stem cell. PLoS Biol 2012;10:e1001407.
38. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005;105:2783-6.
39. Yoder MC. Is endothelium the origin of endothelial progenitor cells? Arterioscler Thromb Vasc Biol 2010;30:1094-103.
40. Berezin AE. Biomarkers for cardiovascular risk in patients with diabetes. Heart 2016;102:1939-41.
41. Qu K, Wang Z, Lin XL, Zhang K, He XL, Zhang H. MicroRNAs: key regulators of endothelial progenitor cell functions. Clin Chim Acta 2015;448:65-73.
42. Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. Acta Clin Belg 2016;71:38-45.
43. Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV, Gronenko EA. Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial-derived and mononuclear-derived progenitor cells in patients with metabolic syndrome. Data Brief 2016;8:717-22.
44. Berezin AE, Samura TA, Kremzer AA, Berezina TA, Martovitskaya YV, Gromenko EA. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients. Diabetes Metab Syndr 2016;10:205-12.
45. Berezin AE, Kremzer AA. Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure. Diabetes Metab Syndr 2014;8:138-44.
46. Berezin AE, Kremzer AA, Samura TA, Berezina TA, Kruzliak P. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. J Endocrinol Invest 2015;38:865-74.
47. Bakogiannis C, Tousoulis D, Androulakis E, Briasoulis A, Papageorgiou N, Vogiatzi G, Kampoli AM, Charakida M, Siasos G, Latsios G, Antoniades C, Stefanadis C. Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes. Curr Med Chem 2012;19:2597-604.
48. Berezin AE, Kremzer AA. Circulating endothelial progenitor cells as markers for severity of ischemic chronic heart failure. J Card Fail 2014;20:438-47.
49. Berezin AE, Kremzer AA, Samura TA, Berezina TA, Martovitskaya YV. Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. J Cardiovasc Thorac Res 2014;6:153-62.
50. Mohandas R, Segal MS. Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease? Blood Purif 2010;29:158-62.
51. Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, Avogaro A. Endothelial progenitor cells and the diabetic paradox. Diabetes Care 2006;29:714-6.
52. Tan K, Lessieur E, Cutler A, Nerone P, Vasanji A, Asosingh K, Erzurum S, Anand-Apte B. Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy. Exp Eye Res 2010;91:229-37.
53. Lombardo MF, Iacopino P, Cuzzola M, Spiniello E, Garreffa C, Ferrelli F, Coppola A, Saccardi R, Piaggesi A, Piro R, Mannino D, Grossi G, Lauro D, Irrera G. Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood. Cytometry A 2012;81:856-64.
54. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 2007;30:1305-13.
55. Ruszkowska-Ciastek B, Sokup A, Leszcz M, Drela E, Stankowska K, Boinska J, Haor B, Ślusarz R, Lisewska B, Gadomska G, Kubica J, Rość D. The number of circulating endothelial progenitor cells in healthy individuals--effect of some anthropometric and environmental factors (a pilot study). Adv Med Sci 2015;60:58-63.
56. Kulwas A, Drela E, Jundziłł W, Góralczyk B, Ruszkowska-Ciastek B, Rość D. Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications. J Diabetes Complications 2015;29:686-90.
57. Nowak WN, Borys S, Kusińska K, Bukowska-Strakova K, Witek P, Koblik T, Józkowicz A, Małecki MT, Dulak J. Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome. J Diabetes Investig 2014;5:99-107.
58. Drela E, Stankowska K, Kulwas A, Rość D. Endothelial progenitor cells in diabetic foot syndrome. Adv Clin Exp Med 2012;21:249-54.
60. Chong AY, Lip GYH, Freestone B, Blann AD. Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin. Eur J Heart Fail 2006;8:167-72.
61. Boos CJ, Lip GYH, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006;48:1538-47.
62. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 2000;65:215-20.
63. Wang C, Li H, Fu P, Zhang S, Xiu R. Serum C-reactive protein and circulating endothelial cells in patients with acute myocardial infarction. Clin Hemorheol Microcirc 2005;32:287-96.
64. Makin AJ, Blann AD, Chung NAY, Silverman SH, Lip GYH. Assessment of endothelial 1018 damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J 2004;25:371-6.
65. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-8.
66. Grochot-Przeczek A, Kotlinowski J, Kozakowska M, Starowicz K, Jagodzinska J, Stachurska A, Volger OL, Bukowska-Strakova K, Florczyk U, Tertil M, Jazwa A, Szade K, Stepniewski J, Loboda A, Horrevoets AJ, Dulak J, Jozkowicz A. Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: role in therapeutic revascularization. Antioxid Redox Signal 2014;20:1677-92.
67. Yoon C-H C, Hur J, Park K-W K, Kim J-H J, Lee C-S C, Oh I-Y I, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005;112:1618-27.
68. Oh IY, Yoon CH, Hur J, Kim JH, Kim TY, Lee CS, Park KW, Chae IH, Oh BH, Park YB, Kim HS. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 2007;110:3891-9.
69. Yoon CH, Hur J, Oh IY, Park KW, Kim TY, Shin JH, Kim JH, Lee CS, Chung JK, Park YB, Kim HS. Intercellular adhesion molecule-1 is upregulated in ischemic muscle, which mediates trafficking of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006;26:1066-72.
70. Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, Kang L, Xu B. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One 2012;7:e50739.
71. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets 2008;9:422-35.
72. Hexum MK, Tian X, Kaufman DS. In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells. Methods Mol Biol 2011;767:433-47.
73. Li B, Cohen A, Hudson TE, Motlagh D, Amrani DL, Duffield JS. Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation 2010;121:2211-20.
74. Kang L, Chen Q, Wang L, Gao L, Meng K, Chen J, Ferro A, Xu B. Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol 2009;36:e47-56.
75. Li Y, Alatan G, Ge Z, Liu D. Effects of benazepril on functional activity of endothelial progenitor cells from hypertension patients. Clin Exp Hypertens 2014;36:545-9.
76. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA. The effect of angiotensin-2 receptor blocker valsartan on circulating level of endothelial progenitor cells in diabetic patients with asymptomatic coronary artery disease. Diabetes Metab Syndr 2015;9:305-9.
77. Raptis AE, Markakis KP, Mazioti MC, Ikonomidis I, Maratou EP, Vlahakos DV, Kotsifaki EE, Voumvourakis AN, Tsirogianni AG, Lambadiari VA, Lekakis JP, Raptis SA, Dimitriadis GD. Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. Am J Hypertens 2015;28:22-9.
78. Suzuki R, Fukuda N, Katakawa M, Tsunemi A, Tahira Y, Matsumoto T, Ueno T, Soma M. Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. Am J Hypertens 2014;27:695-701.
79. Burger D, Touyz RM. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens 2012;6:85-99.
80. Mehta JL, Szwedo J. Circulating endothelial progenitor cells, microparticles and vascular disease. J Hypertens 2010;28:1611-3.
81. Lee CW, Huang PH, Huang SS, Leu HB, Huang CC, Wu TC, Chen JW, Lin SJ. Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic left ventricular hypertrophy. Hypertens Res 2011;34:999-1003.
82. Lineen JR, Kuliszewski M, Dacouris N, Liao C, Rudenko D, Deva DP, Goldstein M, Leong-Poi H, Wald R, Yan AT, Yuen DA. Early outgrowth pro-angiogenic cell number and function do not correlate with left ventricular structure and function in conventional hemodialysis patients: a cross-sectional study. Can J Kidney Health Dis 2015;2:25.
83. Heimrath J, Paprocka M, Czekanski A, Ledwozyw A, Kantor A, Dus D. Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells. Arch Immunol Ther Exp (Warsz) 2014;62:353-6.
84. Grundmann M, Woywodt A, Kirsch T, Hollwitz B, Oehler K, Erdbruegger U, Haller H, Haubitz M. Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol 2008;198:e1-5.
85. Hunting CB, Noort WA, Zwaginga JJ. Circulating endothelial progenitor cells reflect the state of endothelium: vascular injury, repair and neovasculatization. Vox Sang 2005;88:1-9.
86. Eirin A, Zhu XY, Ebrahimi B, Krier JD, Riester SM, van Wijnen AJ, Lerman A, Lerman LO. Intrarenal delivery of mesenchymal stem cells and endothelial progenitor cells attenuates hypertensive cardiomyopathy in experimental renovascular hypertension. Cell Transplant 2015;24:2041-53.
87. Marketou ME, Kalyva A, Parthenakis FI, Pontikoglou C, Maragkoudakis S, Kontaraki JE, Chlouverakis G, Zacharis EA, Patrianakos A, Papadaki HA, Vardas PE. Circulating endothelial progenitor cells in hypertensive patients with increased arterial stiffness. J Clin Hypertens (Greenwich) 2014;16:295-300.
88. Skrzypkowska MW, Ryba-Stanisławowska ME, Słomiński B, Gutknecht PG, Siebert J, Myśliwska JM. Association of circulating progenitor cells with angiotensin II in newly diagnosed hypertensive patients. J Hum Hypertens 2017;32:46-53.
89. Skrzypkowska M, Słomiński B, Ryba-Stanisławowska M, Gutknecht P, Siebert J. Circulating CD34+ and CD34+VEGFR2+ progenitor cells are associated with KLOTHO KL-VS polymorphism. Microvasc Res 2018; doi: 10.1016/j.mvr.2018.03.014.
90. King TF, McDermott JH. Endothelial progenitor cells and cardiovascular disease. J Stem Cells 2014;9:93-106.
91. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, Zulli A, Klimas J, Kruzliak P. The utility of biomarker risk prediction score in patients with chronic heart failure. Int J Clin Exp Med 2015;8:18255-64.
92. Berezin AE, Kremzer AA. Analysis of various subsets of circulating mononuclear cells in asymptomatic coronary artery disease. J Clin Med 2013;2:32-44.
